Abstract
PURPOSE: The evaluation of lymphocyte subsets by using monoclonal antibodies in neoplastic patients has provided different results, partly in relation to the stage of the disease. Therefore, as a preliminary study of cancer patients treated with immunomodulating drugs, an analysis of lymphocyte subsets was performed in colorectal carcinoma patients. METHODS: In this study, a flow cytometric evaluation of lymphocyte subsets was performed in 33 patients affected by colorectal carcinoma, with or without metastases. RESULTS: A significant reduction of hemoglobin concentrations and hematocrit was observed in all of these subjects, associated with an evident increase of white blood cells, platelets, and HLA DR-positive T lymphocytes, whereas CD 3-CD 4-positive and CD 20-positive lymphocyte concentrations were decreased. Subjects without metastases showed an evident decrease of hemoglobin concentrations and an increase of white blood cells, platelets and CD 3-HLA DR-positive lymphocytes, while patients with disseminated disease also had reduced mean values of hematocrit, red blood cells, CD 3-CD 4-positive, and CD 20-positive lymphocytes. CONCLUSIONS: The main differences between colorectal carcinoma patients with or without metastases were represented by a decrease of red blood cells, CD 3-CD 4-positive, and CD 20-positive lymphocyte concentrations in the latter group.
Similar content being viewed by others
References
Von Roenn J, Harris JE, Braun DP. Suppressor cell function in solid tumor cancer patients. J Clin Oncol 1987;5:150–9.
Harris JE, De Boer KP, Vahey AL,et al. The measurement of leukocyte subsets in the peripheral blood of cancer patients with solid tumors using monoclonal antibody reagents. Med Pediatr Oncol 1982;10:185–94.
Karavodin LM, Giuliano AE, Golub SH. T-lymphocyte subsets in patients with malignant melanoma. Cancer Immunol Immunother 1981;11:251–4.
De Boer KP, Braun DP, Harris JE. Natural cytotoxicity and antibody dependent cytotoxicity in solid tumor cancer patients: regulation by adherent cells. Clin Immunol Immunopathol 1982;23:133–44.
Mantovani A, Polentarutti N, Gitti P,et al. K cell activity in ovarian cancer patients given chemotherapy. Eur J Cancer 1979;15:797–802.
Wanebo HJ, Pace R, Hargett S, Katz D, Sando J. Production of and response to interleukin-2 in peripheral blood lymphocytes of cancer patients. Cancer 1986;57:656–62.
Tancini G, Barni S, Rescaldani R, Fiorelli G, Viviani S, Lissoni P. Analysis of T helper and suppressor lymphocyte subsets in relation to the clinical stage of solid neoplasms. Oncology 1990;47:381–4.
Ormerod MG, ed. Flow cytometry. A practical approach. Oxford: IRL Press, 1990.
Cochran AJ, Grant RM, Silg WG,et al. Sensitization to tumor-associated antigens in human breast carcinoma. Int J Cancer 1974;14:19–25.
Steele G, Sjogren HO, Stadenberg I. In vitro cellmediated immune reactions of melanoma and colorectal carcinoma patients demonstrated by long-term 51-chromium assays. Int J Cancer 1976;17:27–9.
Cannon GB, Bonnard GD, Djeu J, West WH, Herberman RB. Relationship of human natural lymphocyte-mediated cytotoxicity to cytotoxicity of breast cancer-derived target cells. Int J Cancer 1977;19:487–97.
Grosser N, Thomson DM. Cell-mediated antitumor immunity in breast cancer patients evaluated by antigen-induced leukocyte adherence inhibition in test tubes. Cancer Res 1975;35:2571–9.
Hellstrom I, Hellstrom KE, Shepard TH. Cell-mediated immunity against antigens common to human colonic carcinomas and fetal gut epithelium. Int J Cancer 1970;6:346–51.
Wanebo HJ, Rao B, Attiyeh F, Pinsky C, Middleman P, Stearns M. Immune reactivity in patients with colorectal cancer: assessment of biologic risk of immunoparameters. Cancer 1980;45:1254–63.
Balch CM, Tilden AB, Dougherty PA, Cloud GA, Abo T. Heterogeneity of natural killer lymphocyte abnormalities in colon cancer patients. Surgery 1984;95:63–70.
Author information
Authors and Affiliations
About this article
Cite this article
Arista, M.C., Callopoli, A., De Franceschi, L. et al. Flow cytometric study of lymphocyte subsets in patients at different stages of colorectal carcinoma. Dis Colon Rectum 37 (Suppl 2), S30–S34 (1994). https://doi.org/10.1007/BF02048428
Issue Date:
DOI: https://doi.org/10.1007/BF02048428